1J5 — Hyphens Pharma International Income Statement
0.000.00%
Last trade - 00:00
- SG$83.48m
- SG$69.72m
- SG$170.60m
- 61
- 77
- 71
- 85
2019 December 31st | C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 119 | 121 | 126 | 162 | 171 |
Cost of Revenue | |||||
Gross Profit | 42.7 | 43.6 | 48.1 | 62.8 | 61.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 111 | 113 | 117 | 147 | 158 |
Operating Profit | 8.61 | 7.65 | 8.55 | 15.6 | 12.6 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 7.99 | 7.11 | 8.26 | 14.3 | 10.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | 6.53 | 6.16 | 6.85 | 11.4 | 8.58 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 6.53 | 6.16 | 6.85 | 11.4 | 8.57 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 6.53 | 6.16 | 6.85 | 11.4 | 8.57 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.022 | 0.019 | 0.022 | 0.035 | 0.028 |
Dividends per Share | |||||
Special Dividends per Share |